Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
Dapagliflozin (Forxiga)HyperglycaemiaGlucocorticoid
Interventions
DRUG

Dapagliflozin (DAPA)

"Participants will receive 10mg/day of dapagliflozin orally. The administration will occur within a synchronous range, meaning that the time difference between dapagliflozin administration and glucocorticoid administration should not exceed 12 hours."

Trial Locations (1)

37366

Unidad Medica de Alta Especialidad Hospital de Especialidades No. 1 CMN Bajio, León

All Listed Sponsors
collaborator

Instituto Mexicano del Seguro Social

OTHER_GOV

lead

Lauro Fabián Amador Medina

OTHER_GOV

NCT06748105 - Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia | Biotech Hunter | Biotech Hunter